Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.

Brendan D CurtiYoshinobu KoguchiRom S LeidnerAnnah S RoligElizabeth R SturgillZhaoyu SunYaping WuVenkatesh RajamanickamBrady BernardIan Hilgart-MartiszusChristopher B FountainGeorge MorrisNoriko IwamotoTakashi ShimadaShuChing ChangPeter G TraberEliezer ZomerJ Rex HortonHarold ShlevinWilliam L Redmond

Published in: Journal for immunotherapy of cancer (2021)

Belapectin+pembrolizumab therapy has activity in MM and HNSCC. Increased Gal-3 expression, expansion of effector memory T cells, and decreased M-MDSCs correlated with clinical response. Further investigation is planned.

Keyphrases

poor prognosis
stem cells
dendritic cells
working memory
mesenchymal stem cells
advanced non small cell lung cancer
cell therapy
tyrosine kinase